Home / Transcripts / Cytek Biosciences, Inc. (CTKB) · May 7, 2026

Cytek Biosciences, Inc. (CTKB) Earnings Call Transcript

May 7, 2026

NASDAQ US Health Care Life Sciences Tools and Services earnings 28 min

Earnings Call Speaker Segments

Paul Goodson executive
#1

Thanks, operator. Cytek Biosciences put out its financial results earlier today for the first quarter, which closed on March 31, 2026. Should you not have gotten that news release, or if you want your name added to the company's distribution list, drop an e-mail to investors@cytekbio.com. You can also find a copy of the news release in the Investor Relations part of Cytek's website, at investors.cytekbio.com. Just so you know, throughout today's call we'll be referencing a slide presentation, and that has been posted to the Investors section of our corporate website. Here with me today from Cytek are Wenbin Jiang, our CEO, and Bill McCombe, our CFO. Before we begin, a quick note about Slide 2: throughout today's call, we'll be sharing forward-looking statements as defined under federal securities laws — this includes things like Cytek's business plans, strategies, opportunities and financial projections. These kinds of statements are based on what the company currently expects, and by their nature they come with substantial risks and uncertainties, which means actual results or events could end up differing materially from what's anticipated. If you want more detail on those risks and uncertainties, you can find it in our slide presentation under the Forward-Looking Statements section, in the press release Cytek put out today, and in the filings Cytek has made with the SEC. Also, during today's call we'll be talking about certain financial measures that aren't calculated in line with generally accepted accounting principles. Details on how we apply non-GAAP financial measures, along with reconciliations to the GAAP figures that are most directly comparable, are available in our slide presentation and in the press release issued today. Although the company considers these non-GAAP financial measures to offer helpful information for investors, presenting this information is not meant to be viewed by itself or as a replacement for financial information reported under GAAP. Cytek won't take on any obligation to revise forward-looking statements unless the law demands it — not for fresh data, not for later occurrences, not for shifts in what it anticipates. The details discussed on this call are tied to a specific moment and hold true solely as of the live webcast on May 7, 2026. Having said that, I'll hand things over to Wenbin.

Wenbin Jiang executive
#2

Thank you, Paul. I'd like to welcome everyone and express our appreciation for your interest in Cytek. To kick off today's call, I want to discuss how we performed during the first quarter of 2026, and after that I'll hand things over to Bill, who will walk through our financials in detail along with our guidance outlook for the entire year. Moving to Slide 3. Revenue for the first quarter of 2026 came in at $44.1 million, which works out to 6% growth year-over-year, up from $41.5 million in Q1 2025. That figure reflects the positive momentum we've continued to see since the second half of 2025, and it represents a solid beginning to the year, along with what looks like a return to normal conditions in the U.S. market, ongoing secular growth throughout APAC with China excluded, recurring revenue growth worldwide, and the breadth of our portfolio. Importantly, we think the revenue growth achieved in the first quarter stands out given the persistent broad market difficulties across the life science tools industry; this result further showcases Cytek's leadership in technology and is likewise demonstrated by robust customer demand for the Cytek Aurora Evo analyzer ever since it was launched last year. On top of that, our expanding installed base keeps driving growth in our service and reagent businesses, as shown by the ongoing increase we see in recurring revenue as a share of total revenue. Moving to Slide 4. In terms of total revenue by geography, U.S. revenue for the first quarter reached $24.4 million, up 32% from $18.5 million in Q1 of last year. Our U.S. strength was broad-based, encompassing sales to top academic institutions as well as biopharma companies. These organizations remain repeat buyers, and a high percentage of them have bought at least 1 instrument from us during the prior 4 quarters. I'm happy to share that our Aurora flagship products keep gaining traction among these buyers, which speaks to how effectively Cytek's products have been meeting the needs of our user base. In EMEA, revenue for the first quarter totaled $10.8 million, a decline of 7% versus Q1 2025. Instrument revenue in that region was weaker during the quarter, attributable to disruption stemming from the conflict in the Middle East plus a shipment delay at quarter end in a different region. Continued growth in our service business partially offset those pressures. APAC, China included, fell 13% year-over-year, mainly because of accelerated order timing in China during the first quarter of last year. With China excluded, the rest of APAC kept demonstrating very strong growth across instruments, reagents and service. Moving to Slide 5. Our recurring revenue base kept getting stronger during the first quarter, with combined reagents and service revenue hitting $18.4 million in the first quarter on a trailing 12-month basis in the first quarter. Recurring revenue accounted for 35% of total revenue and notably rose 19% year-over-year. We anticipate recurring revenue will make up a growing percentage of total revenue over time, powered by faster growth in our service and reagent businesses. Revenue from services by itself climbed 15% compared with the same period a year earlier, reaching $15.4 million, as we kept gaining from an expanding installed base and customers around the globe actively using our instruments. On a percentage basis, reagent revenue rose mid-teens against Q1 of 2025, again mirroring active usage across our installed base. Now I'd like to walk you through how our team has progressed on each of our core strategic pillars — instruments, applications, bioinformatics and clinical — which further cements Cytek's standing as a market leader in next-gen cell analysis solutions. Beginning with our core instruments on Slide 6. During the first quarter we kept widening our global footprint, adding 125 units, which lifted Cytek's total installed base to 3,789 units. A key first-quarter highlight was instrument unit performance, with total unit volume up 9% year-over-year, helped by a 3% year-over-year rise for FSP instruments. We're also encouraged by how the market keeps embracing the Cytek Aurora Evo system. Ever since it launched, it has steadily fueled both revenue and unit volume growth, with revenue for the Aurora analyzer category climbing 8% year-over-year. We think our ongoing emphasis on technological differentiation leaves Cytek well positioned within the broader flow cytometry market. Moving to our next growth pillar, applications, which takes in our reagent business. Versus Q1 2025, reagent revenue was up 16%. Growth in reagent revenue spanned regions broadly, showing particular strength in APAC and the rest of the world regions, where combined reagent revenue rose more than 40% year-over-year, and double digits in the U.S. Our Q1 reagent strength mirrors the ongoing payoff from initiatives we began in 2025, among them best-in-class delivery times, a wider range of reagent offerings and our dedicated reagent sales team. Customer engagement on our bioinformatics platform kept getting deeper, supporting the engine behind our reagent growth. Cytek Cloud had expanded to over 26,000 users as of March 31, 2026, which works out to an average of 8 users for every installed Cytek FSP instrument. As more users join the Cytek Cloud, the value proposition of our integrated ecosystem grows stronger and customer engagement improves. Now to Slide 7. As part of our strategic and business growth process, we have been preparing to refocus operations into 3 distinct customer aligned business units, a move set to finish in the third quarter of this year. The new solutions and clinical business unit will carry successful platforms like reagents, Guava Muse Micro and Northern Light into markets that, historically, larger incumbents dominated, while the research technology business unit will keep advancing Cytek's leadership in high parameter flow cytometry within the research use-only market. This structure will sharpen our focus on aligning marketing, sales and R&D resources so Cytek can expand its share of the reagent and low mid-tier instrument market. Together, these 2 units put Cytek in position to capture 2 major business opportunities. First, for the Solutions and Clinical business unit, growth in reagent consumables and low to mid-tier instruments for QA and QC workflows. Additionally, regarding our research technology segment, there’s a strong replacement cycle underway for high-performance instruments, with tens of thousands of units ultimately requiring substitution. Last but not least, the service division of our company will serve as the backbone sustaining the installed instrument base across both the solutions and clinical and the research technology groups. Taken together, this framework puts Cytek in position to speed up its upcoming growth phase and strengthen our competitive edge as the marketplace changes. Within the newly formed Solutions and Clinical business unit, we identify substantial growth prospects in the clinical research sector, where demand is rising for cell analysis solutions that handle high parameters with top performance; this is partly evident already through a boost in leading sales that back clinical applications. Cytek’s technology platform fits well to enable this scaling, and we are putting resources into addressing the shifting requirements of clinical researchers and translational scientists. At this point, I’d like to invite Bill to go over our financial results.

Bill McCombe executive
#3

Thank you, Wenbin. For the first quarter of 2026, revenue came in at $44.1 million, which is up 6% from the same period a year earlier, when we recorded $41.5 million in Q1 2025. As Wenbin mentioned, the growth was driven by robust performance in U.S. instruments along with ongoing double-digit expansion in both global services and reagents. Those gains were partly offset by disturbances and weaker instrument demand across EMEA, plus the slowdown in APAC tied to order timing. Moving to Slide 8. Product revenue, which includes instruments and reagents, reached $28.8 million, roughly 2% higher than the prior-year period. U.S. product revenue saw a sharp rebound from a soft Q1 '25, getting back to a more typical growth trajectory in line with the years before last year. That improvement came from better sentiment and robust demand growth across both the academic and government and biopharma customer segments. EMEA product revenue fell relative to Q1 '25 because of orders lost to Middle East conflicts, a shipping delay at the end of the quarter in a different region, and weaker instrument demand. In APAC, product revenue also came in lower. The reason was that orders in China shifted forward into Q1 from the first half of last year. Other APAC regions posted very high year-over-year growth in Q1 of this year, and the region's broader secular growth trend is still strong. Reagents kept up their strong growth path, rising 16% quarter-over-quarter, mainly from the U.S. and APAC regions. Service revenue totaled $15.4 million, up 15% year-over-year, fueled by our growing installed base of instruments and active system utilization around the world. Now to total revenues by geographic region. U.S. revenues climbed 32%, powered by a strong rebound in instruments, as I said earlier, and continued growth in services. EMEA declined 7% because of the Middle East conflicts and the end-of-quarter shipping delay I referenced earlier. APAC also dropped 13% due to the order timing issue, as I mentioned before. Moving to Slide 9. GAAP gross profit was $21.3 million in Q1 2026, a gross margin of 48%, versus 49% in Q1 2025. Product gross margin held flat compared to the year-ago quarter, while service gross margin was a bit lower because of higher labor costs. Adjusted gross margin, which strips out stock-based compensation and amortization of acquisition-related intangibles, was 51% in the first quarter versus 52% in the prior-year quarter; for the remaining quarters of this year, we anticipate gross margins will rise as revenue grows, in line with our usual seasonal pattern. Total operating expenses were $39.7 million in Q1, a 13% increase over Q1 of 2025. Research and development expenses were $9.6 million, down 1% from Q1 '25 on lower compensation expenses. Sales and marketing expenses were $11.6 million, down 7% from Q1 '25 due to reduced compensation and selling commission expenses. General and administrative expenses were $18.5 million, up $5.6 million or 43%, with the increase mainly from higher legal expenses tied to the previously disclosed patent litigation case, outside consulting expenses and bad debt reserves. Operational losses came to $18.5 million this quarter, compared with $15 million during the same period last year. On a GAAP basis, our net loss for the first quarter reached $18.9 million, versus a GAAP net loss of $11.4 million a year earlier. That bigger GAAP net loss stemmed mainly from operating expenses that rose by $4.6 million, reduced other income reflecting a $1.2 million foreign exchange loss this quarter against a $1.3 million FX gain in the prior year quarter, and tax expense of $1.5 million compared with $0.1 million of tax expense a year ago. Adjusted EBITDA, which strips out stock-based compensation and foreign exchange effects, showed a loss of $9.1 million in Q1 2026, versus a loss of $3.3 million in Q1 2025. The wider adjusted EBITDA loss was driven mainly by that $4.6 million rise in operating expenses along with $1.8 million less stock-based compensation, which gets added back. We anticipate adjusted EBITDA will grow in the quarters ahead, supported by typical seasonal revenue trends, and that we will achieve positive adjusted EBITDA across the whole of 2026. As of March 31, 2026, cash, cash equivalents and marketable securities came to $262.2 million, up from $261.5 million at the close of 2025. A strong balance sheet like ours keeps giving us the financial flexibility to put money into our global growth priorities. Moving to Slide 10. We are today reaffirming full year 2026 revenue guidance of $205 million to $212 million, on the assumption that currency exchange rates stay unchanged. This outlook captures the positive growth we've recently seen in the U.S. and APAC, plus some stabilization in the EU. With that, I'll hand things back to Wenbin.

Wenbin Jiang executive
#4

Appreciate it, Bill. Let's move on to Slide 11. Before we wrap up, I'd like to express gratitude to the whole Cytek team for the way they keep their attention fixed and keep delivering for both our customers and our shareholders. What we saw in the first quarter speaks to how our business model keeps proving resilient and diversified. Our recurring revenue keeps expanding, and on a trailing 12-month basis it now accounts for 35% of total revenue — which shows how valuable our growing installed base is and how solid our ties with customers have become. As we look at 2026, our priorities haven't shifted and stay straightforward: pushing our instrument platforms deeper into the market, staying at the forefront of technology by innovating without pause, growing that recurring revenue stream, and achieving profitable growth we can sustain; the money we've put into our products, our people and our operational infrastructure, we believe, leaves Cytek positioned strongly for the rest of 2026 and afterward. Thank you all for being on today's call. At this point we'll take questions. Operator?

Harrison Parsons analyst
#5

Harrison here, filling in for Mason. Regarding your 2026 outlook, you're projecting growth of 2% to 5%. Could you take us through what has to go right to reach the upper end, versus what would leave you nearer the bottom of that range for the year?

Bill McCombe executive
#6

Absolutely. Bill here. The method by which we assembled the guidance, and what we're restating today, is ongoing expansion in services and reagents at rates roughly in line with recent quarters. Then flat to slight growth in instruments, and on top of that, the cushion for unexpected or emerging macro risks; that's the structure. We're quite at ease with the growth in services and reagents, the instrument market is — we did observe positive growth in Q1. And we see no reason that ought not to persist. But as everyone knows, macro risks exist out there. So we want a contingency built into our guidance to address things we cannot anticipate right now.

Harrison Parsons analyst
#7

Understood, that clears things up. Next, I was hoping you could tell me how customers break down at present — academic and government accounts compared with biopharma accounts — when it comes to buying the Aurora Evo instrument? Also, could you describe the main advantages that each of those groups of buyers experiences from that product right now?

Bill McCombe executive
#8

We're set to put out shortly, or are on the verge of putting out in the Q, that for the quarter as a whole the split was 62% biopharma distributor CRO and 38% academic and government. That's how Q1 looked. Broadly, for the full year '25, the split stood at 58%, 42%. So it came in somewhat higher. Our biopharma segment delivered a stronger showing. When it comes to Aurora Evo, the figures aren't in front of me, and reporting customer mix at that granularity isn't something we typically do, except to note that this product was truly built with the pharma buyer in mind given its greater throughput, yet it has drawn a strong response from both groups of customers, biopharma as well as academic and government. Wenbin, is there anything you'd like to add?

Wenbin Jiang executive
#9

Exactly. On top of that, integrated intelligence for automatic shutdown and startup is part of it, and all of those things are going to be a real help to researchers when it comes to scheduling and planning. Plus, nanoparticle detection has been integrated into the system as well.

Skye Gilbert analyst
#10

Skye here, filling in for David. Regarding the uncertainty around NIH funding, which was flagged as a risk for 2026, are you noticing any quantifiable effect on demand from U.S. academic and government instrument customers, or on when orders came in during Q1? And how do you view that exposure for the rest of the year?

Bill McCombe executive
#11

In the U.S., academic and government during Q1 rose substantially versus Q1 of last year. It also returned to a level closer to what we'd observed in years before 2Q of 2025. As a matter of fact, it was our best first quarter for U.S. academic and government in quite a few years, possibly ever. So a strong rebound to more typical levels did occur. As for NIH funding, well, we witnessed robust disbursements in Q4 of last year. It appears momentum in the academic and government market continued into Q1. And the budget for the upcoming year is, clearly, still being debated in Congress. The administration's initial proposal wasn't as draconian as last year's initial proposal. So where it ultimately lands remains to be seen; however, during Q1, our performance in the U.S. academic and government sector was quite strong.

Skye Gilbert analyst
#12

And so, when it comes to sales and marketing expenses coming down during Q1, what's your thinking regarding commercial investment over the rest of the year?

Bill McCombe executive
#13

We plan to keep investing at a solid level. That was more a blip for the quarter rather than a trend, though for the balance of the year we expect to go on investing aggressively in sales and marketing.

Operator operator
#14

That brings us to the end of the question-and-answer portion. Today's call has now finished up. Thanks to everyone for being with us, and you're free to hang up at this point.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Cytek Biosciences, Inc. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.

Get an API key View API docs →

For developers and AI pipelines

Programmatic access to Cytek Biosciences, Inc. earnings transcripts and 132,000+ others is available through the EarningsAPI REST API and the hosted MCP server. Quarterly plans from $162 - full transcripts, speaker segments, full-text search, and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.